Pharmaceutical News

RSS

Unbiased, comprehensive analysis of drug research from new web site

Physicians and consumers who want fair and balanced information about the most appropriate uses for prescription medications can now find it using a Web-based resource that provides easily accessible, science-based research about drug uses free from pharmaceutical industry influence.

17 Apr 2008

New type of drug shrinks primary breast cancer tumours significantly in just six weeks

A drug that targets the cell surface receptors that play an important role in many types of cancer can bring about significant tumour regression in breast cancer after only six weeks of use, a scientist told the 6th European Breast Cancer Conference (EBCC-6) (Thursday 17 April).

17 Apr 2008

2nd Alzheimer's vaccine by AFFiRiS

The Viennese biotech company Affiris is today taking stock of the progress achieved to date in its clinical Alzheimer's vaccination programme. All the Alzheimer's patients treated so far as part of the toxicological trials have tolerated the treatment extremely well. As a result, Affiris is among the leading international centres in the race to develop the first causal immunotherapy for Alzheimer's disease.

17 Apr 2008

Drugs in the pipeline: new therapies that could change treatment strategies

The investigational drug AZD2171 (cediranib) may help shrink tumors and prolong survival of patients with a relatively common, aggressive type of brain cancer, according to results from a clinical trial conducted by Boston researchers.

16 Apr 2008

Alcon's PATANASE nasal spray approved by FDA for treatment of nasal allergy symptoms

Alcon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved PATANASE(R) (olopatadine hydrochloride) nasal spray for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older.

16 Apr 2008

Promising Australian cancer drug on show in the U.S.

A cancer drug in the process of being developed by two Australian companies has shown promising results in preliminary trials on animals.

16 Apr 2008

Global Alliance for Pharmacogenomics

Leaders at the National Institutes of Health and the Center for Genomic Medicine in Japan have signed a letter of intent creating a Global Alliance for Pharmacogenomics.

15 Apr 2008

Popular painkiller Nurofen Plus in danger of becoming a prescription only drug

Australia's National Drugs and Poisons Scheduling Committee (NDPSC) is apparently considering making one of the most commonly used over-the-counter (OTC) drugs available only with a prescription.

15 Apr 2008

New mucosal vaccine against anthrax effective in early tests

Early studies show that a new mucosal vaccine against anthrax has the potential to provide military personnel with more effective and efficient protection against a "popular" bioweapon, according to a study published in the journal Clinical and Vaccine Immunology (CVI).

13 Apr 2008

Takeda to acquire Millennium for $8.8 billion

Takeda Pharmaceutical Company Limited and Millennium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement pursuant to which Takeda will acquire Millennium for approximately $8.8 billion through a cash tender offer of $25.00 per share.

10 Apr 2008

Over-the-counter sale of child cough medicine for young children to be banned

As from September this year the over-the-counter sale of cough medicines for children under the age of two years old will be banned in Australia.

9 Apr 2008

New method to detect fake Tamiflu

Chemists in Georgia are reporting development of a fast new method to detect fake Tamiflu, the mainstay medication for preventing and treating bird flu.

8 Apr 2008

FDA approves TREANDA (bendamustine hydrochloride) for chronic lymphocytic leukemia

Cephalon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease, on March 20, 2008.

7 Apr 2008

FDA approves Rotarix

The U.S. Food and Drug Administration has announced the approval of Rotarix, the second oral U.S. licensed vaccine for the prevention of rotavirus, an infection that causes gastroenteritis (vomiting and diarrhea) in infants and children.

4 Apr 2008

Proteolix's Carfilzomib granted orphan drug designation

Proteolix, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to carfilzomib, a selective blocker of proteasome activity for the treatment of multiple myeloma.

3 Apr 2008

Prednisone tablets less variable than marketed drugs

The U.S. Pharmacopeial (USP) Convention has announced results of a study comparing the dissolution variability of USP Prednisone Lot P Reference Standard tablets to two marketed drugs.

2 Apr 2008

Naglazyme approved in Japan

BioMarin Pharmaceutical Inc. has announced that AnGes MG, Inc. (AnGes), BioMarin's marketing and distribution partner in Japan, has received approval for its Marketing Application for Naglazyme(R) (galsulfase) from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with Mucopolysaccharidosis VI ( MPS VI).

1 Apr 2008

FDA deadlines may compromise drug safety by rushing approval

Many medications are approved by the U.S. Food and Drug Administration on the brink of congressionally mandated deadlines, and those drugs are more likely to face later regulatory intervention than those approved with greater deliberation, researchers at Harvard University have found.

28 Mar 2008

Free drug samples may burden patients' pockets

Following free drug sample receipt, patients who receive these samples have significantly higher out-of-pocket prescription costs than those who don't, according to the first study to look at the out-of-pocket cost associated with free-sample use, published in the March 24, 2008, issue of Medical Care.

25 Mar 2008

PharmAthene signs agreement to acquire biodefense vaccines business from Avecia

PharmAthene, Inc., a biodefense company specializing in the development and commercialization of medical countermeasures against biological and chemical threats, and Avecia Biologics Limited, a contract manufacturer of biopharmaceuticals, has announced that the companies have entered into a definitive sale and purchase agreement under which PharmAthene will acquire all of the assets and intellectual property related to Avecia's biodefense vaccines business.

24 Mar 2008